Tuberous sclerosis complex (TSC) is a genetic multisystemic disease that affects approximately 1 in 6,000 live births.1 It causes noncancerous tumors, or hamartomas, to form throughout the body. These benign tumors can develop in many organs, including the brain, eyes, kidneys, liver, lungs, heart, and skin.1
The skin is one of the most affected organs in people with TSC.3
Facial angiofibromas are pink-to-red tumors typically located on the cheeks, nose, and chin, often appearing in a butterfly pattern over the malar eminences and nasolabial folds.1,4
Facial angiofibromas are made up of blood vessels and fibrous tissue and can coalesce to form patches. They can bleed, obstruct the nasal openings, and cause disfigurement.3,5
Facial angiofibroma occurs in approximately 75%-80% of TSC patients, making it the one of the most predominant skin manifestations of this disease.3-5
These tumors are sometimes treated with invasive modalities. However, these procedures may require anesthesia. Invasive treatments can also be difficult to administer in patients with extensive angiofibroma or severe intellectual impairments.4
HYFTOR® is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR®.
WARNINGS AND PRECAUTIONS
The most common adverse reactions (≥1%) are dry skin, application site irritation, pruritus, acne, acneiform dermatitis, ocular hyperemia, skin hemorrhage, and skin irritation.
USE IN SPECIFIC POPULATIONS
Please see full Prescribing Information for additional safety information.